Overview

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Status:
Recruiting
Trial end date:
2024-06-02
Target enrollment:
Participant gender:
Summary
An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Harpoon Therapeutics